Medicare’s artificial intelligence prior authorization pilot program in Washington state has significantly delayed patient care, with previously two-week approval processes now stretching to four to eight weeks, according to a report compiled by Senator Maria Cantwell, D-Wash. The findings raise concerns about the unintended consequences of automation in healthcare administration, particularly for patients requiring timely medical procedures.
The pilot, designed to streamline prior authorization through AI-driven decision support, has instead created bottlenecks that affect access to care across the state. Healthcare providers report increased administrative burdens as they navigate longer wait times for approvals, while patients face delays in receiving necessary treatments. Senator Cantwell’s office emphasized that the report draws from data collected from hospitals, clinics, and medical associations throughout Washington.
Prior authorization is a utilization management process used by health insurers to determine if they will cover a prescribed procedure, service, or medication. Traditionally handled by human reviewers, the integration of AI tools aimed to reduce processing times and administrative costs. However, early implementation in Washington suggests the technology may be exacerbating delays rather than alleviating them, prompting calls for oversight and recalibration of the system.
The issue has drawn attention from both medical professionals and policymakers concerned about equitable access to care. Delays in authorization can lead to worsened health outcomes, increased patient anxiety, and additional strain on an already burdened healthcare infrastructure. Critics argue that without proper safeguards and clinician involvement, AI systems risk prioritizing efficiency over patient needs.
Senator Cantwell, who serves as the Ranking Member of the Senate Commerce Committee, has advocated for greater transparency and accountability in healthcare technology initiatives. Her office confirmed that the report was developed in consultation with stakeholders across Washington’s healthcare sector, including representatives from the Washington State Medical Association and hospital administrators. The senator has called for a pause in the expansion of the AI pilot until further review can assess its impact on patient access.
The Centers for Medicare & Medicaid Services (CMS), which oversees the Medicare program, has not yet issued a public response to the findings. CMS administers prior authorization policies for Medicare Advantage plans and has promoted the use of AI to improve efficiency in utilization management. However, the agency has also acknowledged challenges in balancing automation with clinical judgment, particularly in complex cases requiring nuanced medical review.
Healthcare analysts note that while AI holds promise for reducing administrative waste—estimated at billions of dollars annually in the U.S. Healthcare system—its deployment must be carefully monitored. Factors such as algorithmic bias, lack of provider input in design, and insufficient exception pathways can undermine the intended benefits. In Washington, providers have reported that certain high-volume procedures, including imaging and specialist referrals, are experiencing the most significant delays.
Medical ethicists warn that prolonged prior authorization waits may disproportionately affect vulnerable populations, including elderly patients, those with chronic conditions, and individuals in rural areas with limited access to alternative care options. Timely interventions are often critical in managing conditions such as cancer, cardiovascular disease, and degenerative disorders, where delays can reduce treatment efficacy.
Washington state officials have begun reviewing the report’s implications for state-level healthcare policy. While Medicare is a federal program, state agencies often collaborate with CMS on implementation and oversight. The Washington State Health Care Authority, which administers Medicaid and supports healthcare innovation initiatives, has not announced formal action but is reportedly monitoring the situation.
As the debate over AI in healthcare administration continues, stakeholders agree that any technological solution must prioritize patient outcomes, maintain clinician oversight, and include robust mechanisms for appeal and expedited review. Senator Cantwell has indicated she will pursue legislative oversight to ensure that future pilots incorporate real-world feedback and avoid compromising access to care in the name of efficiency.
For now, patients and providers in Washington navigate a system where the promise of AI-enabled speed has given way to extended uncertainty. Until the pilot is reassessed and adjusted, the four- to eight-week wait for prior authorization remains a tangible barrier to timely medical care, underscoring the need for vigilant implementation of emerging technologies in health policy.
Readers seeking updates on this issue can monitor official communications from Senator Cantwell’s office, the Senate Commerce Committee, and the Centers for Medicare & Medicaid Services. Healthcare providers are encouraged to document delays and share experiences with professional associations advocating for reform in prior authorization practices.